These pathologies are characterized by increased biliary senescence and changes in intrahepatic bile duct mass (IBDM), enhanced 3′,5′-cyclic cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2) signaling and liver fibrosis that can be triggered by paracrine mechanisms through the release of biliary senescence-associated secretory phenotypes (SASPs) such as transforming growth factor- β1 (TGF-β1) [10,11,12]. This evidence concerns the gene MAPK3 and Hepatic fibrosis.